Metabolic health profile in young adults with Prader–Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial

Clinical Endocrinology

Volumn 86, Issue 2, 2017, Pages 297-304

  Kuppens, R J ^a,b   Bakker, N E ^a,b   Siemensma, E P C ^a,b   Donze, S H ^a,b   Stijnen, T ^c   Hokken Koelega, A C S ^a,b  

^a Dutch Growth Research Foundation   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HORMONE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG ADULT; ADOLESCENT; ANALYSIS; BLOOD; GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PRADER-WILLI SYNDROME;

ADOLESCENT; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN; MALE; PRADER-WILLI SYNDROME; YOUNG ADULT;

EID: 84995899357     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13247     Document Type: Article

References (38)

1. Goldstone, A.P., Holland, A.J., Hauffa, B.P. et al. (2008) Recommendations for the diagnosis and management of Prader–Willi syndrome. Journal of Clinical Endocrinology and Metabolism, 93, 4183–4197.
2. Cassidy, S.B. (1997) Prader–Willi syndrome. Journal of Medical Genetics, 34, 917–923.
3. Eiholzer, U., Bachmann, S. & l'Allemand, D. (2000) Is there growth hormone deficiency in Prader–Willi Syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader–Willi syndrome. Hormone Research, 53(Suppl 3), 44–52.
4. Holm, V.A., Cassidy, S.B., Butler, M.G. et al. (1993) Prader–Willi syndrome: consensus diagnostic criteria. Pediatrics, 91, 398–402.
5. Bakker, N.E., Kuppens, R.J., Siemensma, E.P. et al. (2013) Eight years of growth hormone treatment in children with Prader–Willi syndrome: maintaining the positive effects. Journal of Clinical Endocrinology and Metabolism, 98, 4013–4022.
6. Emerick, J.E. & Vogt, K.S. (2013) Endocrine manifestations and management of Prader–Willi syndrome. International Journal of Pediatric Endocrinology, 2013, 14.
7. Brambilla, P., Bosio, L., Manzoni, P. et al. (1997) Peculiar body composition in patients with Prader-Labhart-Willi syndrome. American Journal of Clinical Nutrition, 65, 1369–1374.
8. Bekx, M.T., Carrel, A.L., Shriver, T.C. et al. (2003) Decreased energy expenditure is caused by abnormal body composition in infants with Prader–Willi Syndrome. Journal of Pediatrics, 143, 372–376.
9. Bakker, N.E., Kuppens, R.J., Siemensma, E.P. et al. (2015) Bone mineral density in children and adolescents with Prader–Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. Journal of Clinical Endocrinology and Metabolism, 100, 1609–1618.
10. Festen, D.A., Wevers, M., Lindgren, A.C. et al. (2008) Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader–Willi syndrome. Clinical Endocrinology, 68, 919–925.
11. Siemensma, E.P., Tummers-de Lind van Wijngaarden, R.F., Festen, D.A. et al. (2012) Beneficial effects of growth hormone treatment on cognition in children with Prader–Willi syndrome: a randomized controlled trial and longitudinal study. Journal of Clinical Endocrinology and Metabolism, 97, 2307–2314.
12. Lo, S.T., Festen, D.A., Tummers-de Lind van Wijngaarden, R.F. et al. (2015) Beneficial effects of long-term growth hormone treatment on adaptive functioning in infants with Prader–Willi syndrome. American Journal on Intellectual Developmental Disabilities, 120, 315–327.
13. Kuppens, R.J., Bakker, N.E., Siemensma, E.P.C. et al. (2016) Beneficial effects of growth hormone in young adults with Prader–Willi syndrome: results of a 2-year randomized, double-blind, placebo-controlled cross-over trial. Journal of Clinical Endocrinology and Metabolism, 101, 4110–4116.
14. Nagai, T. & Mori, M. (1999) Prader–Willi syndrome, diabetes mellitus and hypogonadism. Biomedicine & Pharmacotherapy, 53, 452–454.
15. Laurier, V., Lapeyrade, A., Copet, P. et al. (2015) Medical, psychological and social features in a large cohort of adults with Prader–Willi syndrome: experience from a dedicated centre in France. Journal of Intellectual Disability Research, 59, 411–421.
16. Hoybye, C., Hilding, A., Jacobsson, H. et al. (2003) Growth hormone treatment improves body composition in adults with Prader–Willi syndrome. Clinical Endocrinology, 58, 653–661.
17. Sode-Carlsen, R., Farholt, S., Rabben, K.F. et al. (2010) One year of growth hormone treatment in adults with Prader–Willi syndrome improves body composition: results from a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 95, 4943–4950.
18. Senn, S. (1994) The AB/BA crossover: past, present and future? Statistical Methods in Medical Research, 3, 303–324.
19. World Health Organization (2006) Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. World Health Organization.
20. Fredriks, A.M., van Buuren, S., Wit, J.M. et al. (2000) Body index measurements in 1996–7 compared with 1980. Archives of Disease in Childhood, 82, 107–112.
21. Fredriks, A.M., van Buuren, S., Burgmeijer, R.J. et al. (2000) Continuing positive secular growth change in The Netherlands 1955–1997. Pediatric Research, 47, 316–323.
22. Rosner, B., Prineas, R.J., Loggie, J.M. et al. (1993) Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. Journal of Pediatrics, 123, 871–886.
23. Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499–502.
24. Kuppens, R.J., Diene, G., Bakker, N.E. et al. (2015) Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader–Willi syndrome. Endocrine, 50, 633–642.
25. Rikken, B., van Doorn, J., Ringeling, A. et al. (1998) Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Hormone Research, 50, 166–176.
26. van der Steen, M., Lem, A.J., van der Kaay, D.C. et al. (2015) Metabolic health in short children born small for gestational age treated with growth hormone and gonadotropin-releasing hormone analog: results of a randomized, dose-response trial. Journal of Clinical Endocrinology and Metabolism, 100, 3725–3734.
27. Grundy, S.M., Cleeman, J.I., Daniels, S.R. et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735–2752.
28. Sanchez-Ortiga, R., Klibanski, A. & Tritos, N.A. (2012) Effects of recombinant human growth hormone therapy in adults with Prader–Willi syndrome: a meta-analysis. Clinical Endocrinology, 77, 86–93.
29. Maison, P., Griffin, S., Nicoue-Beglah, M. et al. (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 89, 2192–2199.
30. Mekala, K.C. & Tritos, N.A. (2009) Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. Journal of Clinical Endocrinology and Metabolism, 94, 130–137.
31. Talebizadeh, Z. & Butler, M.G. (2005) Insulin resistance and obesity-related factors in Prader–Willi syndrome: comparison with obese subjects. Clinical Genetics, 67, 230–239.
32. Grugni, G., Crino, A., Bedogni, G. et al. (2013) Metabolic syndrome in adult patients with Prader–Willi syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 23, 1134–1140.
33. Zipf, W.B. (1999) Glucose homeostasis in Prader–Willi syndrome and potential implications of growth hormone therapy. Acta Paediatrica. Supplement, 88, 115–117.
34. Festen, D.A., van Toorenenbergen, A., Duivenvoorden, H.J. et al. (2007) Adiponectin levels in prepubertal children with Prader–Willi syndrome before and during growth hormone therapy. Journal of Clinical Endocrinology and Metabolism, 92, 1549–1554.
35. Pagano, C., Marin, O., Calcagno, A. et al. (2005) Increased serum resistin in adults with Prader–Willi syndrome is related to obesity and not to insulin resistance. Journal of Clinical Endocrinology and Metabolism, 90, 4335–4340.
36. Smith, A.G. & Muscat, G.E. (2005) Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. International Journal of Biochemistry & Cell Biology, 37, 2047–2063.
37. Mokdad, A.H., Ford, E.S., Bowman, B.A. et al. (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 289, 76–79.
38. Angulo, M.A., Butler, M.G. & Cataletto, M.E. (2015) Prader–Willi syndrome: a review of clinical, genetic, and endocrine findings. Journal of Endocrinological Investigation, 38, 1249–1263.